Screening the General Population for SARS-CoV-2 Virus and COVID-19 Antibodies: A Counterargument
- PMID: 32609341
- PMCID: PMC7337818
- DOI: 10.1093/jalm/jfaa104
Screening the General Population for SARS-CoV-2 Virus and COVID-19 Antibodies: A Counterargument
Comment in
-
SARS-CoV-2 Serology-Need for Quantitative Testing and Interpretive Reporting.J Appl Lab Med. 2020 Nov 1;5(6):1420-1422. doi: 10.1093/jalm/jfaa147. J Appl Lab Med. 2020. PMID: 32780822 Free PMC article. No abstract available.
References
-
- US Food and Drug Administration. Insight into FDA’s revised policy on antibody tests: prioritizing access and accuracy. https://www.fda.gov/news-events/fda-voices/insight-fdas-revised-policy-a... (Accessed May 2020).
-
- Rhoads DD, Cherian SS, Roman K, Stampa LM, Schmoozer CL, Sadri N.. Comparison of Abbott ID Now, Diasporic Simplex, and CDC FDA EUA methods for the detection of SARS-CoV-2 from nasoparyngeal and nasal swabs from individuals diagnosed with COVID-19. J Clin Microbiol 2020. doi: 10.1128/JCM.00760-20. - DOI - PMC - PubMed
-
- Whitman JD, Hiatt J, Mowery CT, Shy BR, Yu R, Yamamoto TN, et al. Test performance evaluation of SARS-CoV-2 serological assays. medRxiv 2020. doi: 10.1101/2020.04.25.20074856. - DOI
-
- US Food and Drug Administration. EAU authorized serology test performance. https://www.fda.gov/medical-devices/emergency-situations-medical-devices... (Accessed May 2020).